The role of natalizumab in hematopoietic stem cell mobilization.
The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.
Neumann
Frank
F
Heinrich-Heine-University, Department of Hematology, Oncology and Clinical Immunology, Duesseldorf, Germany. Frank.Neumann@med.uni-duesseldorf.de
Zohren
Fabian
F
Haas
Rainer
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34 / Q000096:biosynthesis; D002986:Clinical Trials as Topic; D006402:Hematologic Diseases / Q000628:therapy; D019337:Hematologic Neoplasms / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D008954:Models, Biological; D009103:Multiple Sclerosis / Q000628:therapy; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34; D000069442:Natalizumab